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 In Europe, low seropositivity may be noted in Scandinavia & 
Finland: 
◦ Norway (pregnant):   8.3-10.4%,  
◦ Sweden (women):     11-25%,  
◦ Denmark (pregnant): 26.8-27.4% 
◦ Finland (pregnant):    20% 
 Seropositivity in France has decreased from 83% (1965) to 54% 
(1995), 44% in 2005 and now ~37% [1].  
 German figures (male and female) show 55% seropositivity [2]. 
 Netherlands (women): 35.2% [3]. 
 In USA (NHANES 2009-2010) → 12.4% (9.1% women) [4]. 




 T. gondii seropositivity (%) 
in pregnant women in 
Poland may vary among 
voivodeships (regions). 
 Polish reports show a 
relatively high prevalence 
of T. gondii → 36-58% 
[5,6]. 
 Cracow is located in 
Poland (Małopolskie 
voivodeship) and the 








 Standard diagnostics: IgG, IgM; IgG avidity. 
 High avidity usually excludes recent infection (careful in 3rd trim). 
But low IgG avidity may persist for many months after infection. 
 Sabin-Feldman dye test: not so common nowadays (requires 
animal house, live parasite and complement) – but tells the 
global Ig against parasite; 1:1000. 
 There may be some difficulties interpreting the results with 
regards to the phase of infection in pregnancy. E.g. IgM may be 
detected even 9 months since infection or longer (in only 25%, 
IgM lowers up to 7 months). Avidity may be bordeline. 
 Always good to verify results in a reference lab and with any 





1. Precise detection of the moment of infection with Toxoplasma gondii 
in a pregnant woman plays a key role in determining the risk of 
transmission to the foetus.  
2. In my opinion, diagnostic screeening and examination for 
Toxoplasma should be performed as soon as possible, best even 
before the planned pregnancy and in the beginning of the 1st 
trimester and monitored in seronegative women throughout 
pregnancy. 
3. PROBLEMS: Sometimes the first Toxoplasma screening is only done 
later in pregnancy or close to term, when even the lack of specific 
IgM and high IgG avidity using traditional immunodiagnostic 
methods with native antigen does not allow to exclude early T. gondii 
infection with 100% certainty. Furthermore, diagnosis of infection 
often requires collection of two blood samples in 2-3 week period 
which may be difficult close to term. 
 
 AIMS: 
◦ Patient infected: YES/NO 
◦ NB! If YES estimation of the stage/phase of infection – 
primary vs. past infection. If NO (seronegative) close monitoring. 
 Questions to be answered:  
   has there been a primary infection with T. gondii and 
whether there is a risk for vertical transmission of the 
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infection (%) 
Risk of clinical 




Risk for fetal infection and clinical symptoms 









Overall risk ~ 40% 
[7] Montoya JG, 
Remington. CID 
2008;47:554-66 
MATERIALS AND METHODS 
 
Patients analysed consisted of women between ages 26-35, in whom 
IgG, IgM presence/titers and IgG avidity was tested using ELISA-
VIDITEST Toxo IgG/IgM (Vidia) and ELISA Avidity-TOXO 
(EUROIMMUNE).  
 
In doubtful cases presence of IgG and IgM was tested additionally for 
recombinant T. gondii antigens: ROP1c, MIC3, GRA7, GRA8, p30, 
MAG1, GRA1, rSAG1 and IgG avidity for p30, MAG1, GRA1, and 
rSAG1 using recomLine Toxoplasma tests (Mikrogen Diagnostik). 
Results were read automatically and interpreted with BLOTrix-Reader 
and phases of infection (I, II, III, IV) were determined according to test 
producer’s instructions.  
 







Name of  
recombinant antigen 
Lifecycyle form Antibodies detected 
Rhoptry antigen ROP1c  tachyzoites/bradyzoites 
mainly IgM, 
less commonly IgG 
Microneme antigen MIC3 tachyzoites IgM 
Dense granule antigens 
GRA1 
Used in avidity studies 
tachyzoites/bradyzoites IgG 
GRA7 tachyzoites/bradyzoites IgM, IgG 
GRA8 tachyzoites/bradyzoites IgM, IgG 
Surface antigens 
P30 




Used in avidity studies 
tachyzoites IgG 
Tissue cyst matrix 
antigen 
MAG1 
Used in avidity studies 
bradyzoites/tachyzoites IgG 
Time of T.gondii infection tested using immunoblotting with 
recombinant antigens in pregnant women 
recomLine Toxoplasma tests (Mikrogen Diag.) 
To show the 
usefulness of the 





32 week of pregnancy  
 
Standard ELISA testing:  
border values for IgM (1.0) 
positive IgG (192 IU/ml)  
high IgG avidity (87%) 
 
recomLine test results: 
positive IgM for ROP1c 
high IgG avidity to p30, GRA1  
low to rSAG1 
 
CONCLUSION: 
II phase of infection (last 3-6 months) 
primary toxoplasmosis  
during pregnancy,  
having in mind the 32 hbd.  
PATIENT 2 
 
30 week of pregnancy  
 
Standard ELISA testing: 
IgG of 198 IU/ml  
no IgM  
IgG avidity of 80% 
 
recomLine test results: 
high IgG avidity to p30,  




IV phase of infection (> 12 months) 




17 week of pregnancy  
 
Standard ELISA testing:  
IgM (1.7)  
IgG (187 IU/ml)  
borderline avidity of 47% 
 
recomLine test results: 
positive IgM for ROP1c and GRA8  
low IgG avidity to p30 and GRA1 
 
CONCLUSION: 
I phase of infection (0-3 months) 
primary toxoplasmosis  
during pregnancy.  
CONCLUSION 
 
recomLine Toxoplasma test, which is based on 
recombinant antigens, facilitates differentiation of 
acute from chronic T. gondii infection and allows to 
determine the time since infection and the risk of 
transmission to the foetus, without the need to collect 
consecutive blood samples.  
 
It may be useful especially in pregnant women, who 
only have their first diagnostic toxoplasma screening 
done in the II or III trimester of pregnancy.  
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